• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性肺纤维化:诊断时功能特征的新见解

Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis.

作者信息

Cortes-Telles Arturo, Forkert Lutz, O'Donnell Denis E, Moran-Mendoza Onofre

出版信息

Can Respir J. 2014 May-Jun;21(3):e55-60. doi: 10.1155/2014/825606. Epub 2014 Apr 7.

DOI:10.1155/2014/825606
PMID:24712014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4128468/
Abstract

BACKGROUND

The lung function of patients with idiopathic pulmonary fibrosis (IPF) has not been characterized in detail. objective: To characterize the heterogeneous physiological abnormalities that exist in patients with IPF during their initial clinical evaluation.

METHODS

Lung function tests from 93 patients, performed within six months of the initial diagnosis of IPF, were obtained from a referral pulmonary function laboratory at a tertiary care hospital in Canada. A restrictive pattern was defined as total lung capacity (TLC) <95th percentile of predicted value. Patients with obstructive lung disease, lung cancer, emphysema and other restrictive lung diseases were excluded.

RESULTS

On diagnosis, 73% of patients with IPF had a restrictive pattern, with a mean TLC of 72% of predicted. Mean forced vital capacity (FVC) was 71% and 44% of patients had an FVC <95th percentile. Mean diffusing capacity for carbon monoxide (DLCO) was 60% and DLCO⁄alveolar volume (VA) 92% of predicted. Increased severity of restriction - based on TLC - was associated with lower DLCO (74% of predicted in mild restriction and 39% of predicted in severe restriction) and higher forced expiratory volume in 1 s (FEV1)⁄FVC ratio (82% of predicted in mild restriction and 90% of predicted in severe restriction) but not with age (76 years in mild restriction and 69 years in severe restriction). Regardless of severity of restriction, the average DLCO⁄VA (≥86% of predicted) remained within normal limits.

CONCLUSIONS

One in four patients with IPF had normal TLC and more than one-half had a normal FVC during initial evaluation. As the severity of the restriction increased, FEV1⁄FVC increased, DLCO decreased but DLCO⁄VA remained normal.

摘要

背景

特发性肺纤维化(IPF)患者的肺功能尚未得到详细描述。目的:描述IPF患者在初次临床评估时存在的异质性生理异常。

方法

从加拿大一家三级护理医院的转诊肺功能实验室获取了93例IPF患者在初次诊断后6个月内进行的肺功能测试结果。限制性模式定义为肺总量(TLC)<预测值的第95百分位数。排除患有阻塞性肺疾病、肺癌、肺气肿和其他限制性肺疾病的患者。

结果

诊断时,73%的IPF患者存在限制性模式,平均TLC为预测值的72%。平均用力肺活量(FVC)为预测值的71%,44%的患者FVC<第95百分位数。平均一氧化碳弥散量(DLCO)为预测值的60%,DLCO/肺泡容积(VA)为预测值的92%。基于TLC的限制性严重程度增加与较低的DLCO(轻度限制性时为预测值的74%,重度限制性时为预测值的39%)和较高的1秒用力呼气量(FEV1)/FVC比值(轻度限制性时为预测值的82%,重度限制性时为预测值的90%)相关,但与年龄无关(轻度限制性时为76岁,重度限制性时为69岁)。无论限制性严重程度如何,平均DLCO/VA(≥预测值的86%)仍在正常范围内。

结论

在初次评估时,四分之一的IPF患者TLC正常,超过一半的患者FVC正常。随着限制性严重程度的增加,FEV1/FVC增加,DLCO降低,但DLCO/VA仍保持正常。

相似文献

1
Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis.特发性肺纤维化:诊断时功能特征的新见解
Can Respir J. 2014 May-Jun;21(3):e55-60. doi: 10.1155/2014/825606. Epub 2014 Apr 7.
2
Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study.特发性肺纤维化的定量 CT 分析及其与肺功能研究的相关性。
BMC Pulm Med. 2024 Sep 5;24(1):437. doi: 10.1186/s12890-024-03254-9.
3
Influence of radiological emphysema on lung function test in idiopathic pulmonary fibrosis.放射性肺气肿对特发性肺纤维化肺功能检查的影响。
Respir Med. 2013 Nov;107(11):1781-8. doi: 10.1016/j.rmed.2013.08.039. Epub 2013 Sep 3.
4
Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis.肺活检对特发性肺纤维化患者肺功能的影响。
Respiration. 2020;99(12):1101-1108. doi: 10.1159/000509557. Epub 2020 Dec 1.
5
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.重组人 Pentraxin 2 与安慰剂对特发性肺纤维化患者用力肺活量变化的影响:一项随机临床试验。
JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.
6
Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.特发性肺纤维化合并轻度生理损害的疾病进展:来自澳大利亚特发性肺纤维化登记处的分析。
BMC Pulm Med. 2018 Jan 25;18(1):19. doi: 10.1186/s12890-018-0575-y.
7
Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.新诊断特发性肺纤维化日本患者用力肺活量的 6 个月连续变化可预测随后的下降和死亡率。
Respir Investig. 2021 May;59(3):335-341. doi: 10.1016/j.resinv.2020.12.008. Epub 2021 Feb 4.
8
[Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].[抗合成酶综合征相关间质性肺病和特发性肺纤维化中肺功能检查及KL-6的特征与临床意义]
Zhonghua Yi Xue Za Zhi. 2020 Mar 17;100(10):748-752. doi: 10.3760/cma.j.cn112137-20191008-02166.
9
Idiopathic pulmonary fibrosis and emphysema in smokers.吸烟者的特发性肺纤维化和肺气肿
J Bras Pneumol. 2008 Oct;34(10):779-86. doi: 10.1590/s1806-37132008001000005.
10
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验:吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.

引用本文的文献

1
Greater large conducting airway luminal area in adult patients with interstitial lung disease.成年间质性肺疾病患者较大的大气道管腔面积。
Physiol Rep. 2025 Sep;13(18):e70578. doi: 10.14814/phy2.70578.
2
A combined measure of blood leukocytes, forced vital capacity and quantitative CT is highly predictive of mortality in IPF: results of a single-centre cohort study.血液白细胞、用力肺活量和定量CT的综合指标对特发性肺纤维化患者的死亡率具有高度预测性:一项单中心队列研究的结果
BMC Pulm Med. 2025 Jul 28;25(1):358. doi: 10.1186/s12890-025-03825-4.
3
Greater Large Conducting Airway Luminal Area in Patients with Interstitial Lung Disease.间质性肺疾病患者的大气道管腔面积增大
medRxiv. 2025 Apr 6:2025.04.04.25324181. doi: 10.1101/2025.04.04.25324181.
4
Imaging of Pulmonary Sarcoidosis-A Review.肺结节病的影像学——综述
J Clin Med. 2024 Jan 31;13(3):822. doi: 10.3390/jcm13030822.
5
Harnessing the translational power of bleomycin model: new insights to guide drug discovery for idiopathic pulmonary fibrosis.利用博来霉素模型的转化能力:为特发性肺纤维化药物研发提供指导的新见解。
Front Pharmacol. 2023 Nov 30;14:1303646. doi: 10.3389/fphar.2023.1303646. eCollection 2023.
6
Precision medicine advances in idiopathic pulmonary fibrosis.特发性肺纤维化的精准医学进展。
EBioMedicine. 2023 Sep;95:104766. doi: 10.1016/j.ebiom.2023.104766. Epub 2023 Aug 23.
7
Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks.特发性肺纤维化与新冠后肺纤维化:关联与风险
Microorganisms. 2023 Mar 30;11(4):895. doi: 10.3390/microorganisms11040895.
8
Fibrotic-like abnormalities notably prevalent one year after hospitalization with COVID-19.纤维化样异常在 COVID-19 住院一年后显著普遍。
Respir Med Res. 2022 Nov;82:100973. doi: 10.1016/j.resmer.2022.100973. Epub 2022 Nov 17.
9
Air pollution enhance the progression of restrictive lung function impairment and diffusion capacity reduction: an elderly cohort study.空气污染加剧了限制性肺功能损害和弥散能力降低的进展:一项老年队列研究。
Respir Res. 2022 Jul 14;23(1):186. doi: 10.1186/s12931-022-02107-5.
10
Respiratory Impedance is Associated with Ventilation and Diffusing Capacity in Patients with Idiopathic Pulmonary Fibrosis Combined with Emphysema.特发性肺纤维化合并肺气肿患者的呼吸阻抗与通气和弥散能力相关。
Int J Chron Obstruct Pulmon Dis. 2022 Jul 1;17:1495-1506. doi: 10.2147/COPD.S368162. eCollection 2022.

本文引用的文献

1
Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.特发性肺纤维化中合并性肺纤维化和肺气肿的临床特征和转归。
Chest. 2013 Jul;144(1):234-240. doi: 10.1378/chest.12-2403.
2
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化(CAPACITY)患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.
3
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.特发性肺纤维化:诊断和管理的循证指南(美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布)
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
4
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.肺功能测量在特发性肺纤维化和合并肺纤维化和肺气肿患者中的死亡率预测作用不同。
Eur Respir J. 2011 Jul;38(1):176-83. doi: 10.1183/09031936.00114010. Epub 2010 Dec 9.
5
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.特发性肺纤维化的临床病程和生存预测。
Am J Respir Crit Care Med. 2011 Feb 15;183(4):431-40. doi: 10.1164/rccm.201006-0894CI. Epub 2010 Oct 8.
6
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.伊马替尼治疗特发性肺纤维化:随机安慰剂对照试验结果。
Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.
7
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.用力肺活量呈边际下降与特发性肺纤维化的不良预后相关。
Eur Respir J. 2010 Apr;35(4):830-6. doi: 10.1183/09031936.00155108. Epub 2009 Oct 19.
8
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.BUILD-1:波生坦治疗特发性肺纤维化的随机安慰剂对照试验。
Am J Respir Crit Care Med. 2008 Jan 1;177(1):75-81. doi: 10.1164/rccm.200705-732OC. Epub 2007 Sep 27.
9
Early interstitial lung disease in familial pulmonary fibrosis.家族性肺纤维化中的早期间质性肺疾病
Am J Respir Crit Care Med. 2007 Oct 1;176(7):698-705. doi: 10.1164/rccm.200702-254OC. Epub 2007 Jul 19.
10
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.特发性肺纤维化:生理学变化及六分钟步行试验的预后价值
Am J Respir Crit Care Med. 2006 Oct 1;174(7):803-9. doi: 10.1164/rccm.200604-488OC. Epub 2006 Jul 6.